Livzon Pharmaceutical Group's significant public companies ownership suggests that the key decisions are influenced by shareholders from the larger public
The top 8 shareholders own 50% of the company
Institutions own 15% of Livzon Pharmaceutical Group
Every investor in Livzon Pharmaceutical Group Inc. (SZSE:000513) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are public companies with 44% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
And individual investors on the other hand have a 38% ownership in the company.
In the chart below, we zoom in on the different ownership groups of Livzon Pharmaceutical Group.
SZSE:000513 Ownership Breakdown November 22nd 2024
What Does The Institutional Ownership Tell Us About Livzon Pharmaceutical Group?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
We can see that Livzon Pharmaceutical Group does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Livzon Pharmaceutical Group's earnings history below. Of course, the future is what really matters.
SZSE:000513 Earnings and Revenue Growth November 22nd 2024
We note that hedge funds don't have a meaningful investment in Livzon Pharmaceutical Group. Joincare Pharmaceutical Group Industry Co.,Ltd. is currently the largest shareholder, with 44% of shares outstanding. Guangzhou Begol Trading Corporation is the second largest shareholder owning 1.9% of common stock, and UBS Asset Management AG holds about 1.4% of the company stock.
We also observed that the top 8 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent.
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.
Insider Ownership Of Livzon Pharmaceutical Group
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
Our most recent data indicates that insiders own less than 1% of Livzon Pharmaceutical Group Inc.. However, it's possible that insiders might have an indirect interest through a more complex structure. It's a big company, so even a small proportional interest can create alignment between the board and shareholders. In this case insiders own CN¥121m worth of shares. Arguably, recent buying and selling is just as important to consider. You can click here to see if insiders have been buying or selling.
General Public Ownership
The general public-- including retail investors -- own 38% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
Public Company Ownership
We can see that public companies hold 44% of the Livzon Pharmaceutical Group shares on issue. This may be a strategic interest and the two companies may have related business interests. It could be that they have de-merged. This holding is probably worth investigating further.
Next Steps:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. Take risks for example - Livzon Pharmaceutical Group has 1 warning sign we think you should be aware of.
But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Livzon Pharmaceutical Group Inc.(SZSE:000513)の投資家は、最も影響力のある株主グループを認識しておくべきです。そして、最も大きなシェアを持っているグループは、44%の所有権を持つ公開企業です。言い換えれば、このグループは会社への投資から最も利益を得る(または最も損失を被る)可能性が高いです。
最新のデータによれば、インサイダーはLivzon Pharmaceutical Group Inc.の株式の1%未満を保有しています。しかし、インサイダーがより複雑な構造を通じて間接的な利害関係を持っている可能性があります。大きな会社なので、少しの割合の利害関係でも取締役会と株主との間に整合性を生むことができます。この場合、インサイダーはCN¥12100万相当のシェアを所有しています。最近の売買も同様に重要な要因と考えられます。インサイダーが買いまたは売りを行っているか確認するには、こちらをクリックしてください。
オーストラリアでは、moomooの投資商品及びサービスはMoomoo Securities Australia Limitedによって提供され、オーストラリア証券投資委員会(ASIC)の管理を受けております(AFSL No. 224663)。「金融サービスガイド」、「利用規約」、「プライバシーポリシー」などの詳細は、Moomoo Securities Australia Limitedのウェブサイトhttps://www.moomoo.com/auでご確認いただけます。
オーストラリアでは、moomooの投資商品及びサービスはMoomoo Securities Australia Limitedによって提供され、オーストラリア証券投資委員会(ASIC)の管理を受けております(AFSL No. 224663)。「金融サービスガイド」、「利用規約」、「プライバシーポリシー」などの詳細は、Moomoo Securities Australia Limitedのウェブサイトhttps://www.moomoo.com/auでご確認いただけます。